# Evaluation of a Booster Administration of GAD-alum (Diamyd®) in Individuals With Type 1 Diabetes

> **NCT05351879** · PHASE1,PHASE2 · COMPLETED · sponsor: **Linkoeping University** · enrollment: 6 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **BIOLOGICAL:** GAD-alum (Diamyd) 40 μg/mL

## Key facts

- **NCT ID:** NCT05351879
- **Lead sponsor:** Linkoeping University
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-09
- **Primary completion:** 2023-08-29
- **Final completion:** 2023-08-29
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2023-12-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05351879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05351879, "Evaluation of a Booster Administration of GAD-alum (Diamyd®) in Individuals With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05351879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*